Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

50.64 +3.18 (+6.70%)
Streaming Delayed Price Updated: 2:43 PM EDT, Aug 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about uniQure N.V. - Ordinary Shares

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
17 18 Next >
News headline image
UniQure Stock Hits 5-Year High As Analysts Hail Huntington’s Therapy Data — Retail Spots ‘Diamond In Rough Of Biotech’ ↗
UniQure said the high-dose of its AMT-130 therapy slowed Huntington’s disease progression by up to 75% over three years and plans to seek FDA approval in early 2026. 
Via Stocktwits
News headline image
uniQure Announces $200 Million Proposed Public Offering
From uniQure Inc.
Via GlobeNewswire
News headline image
Nasdaq Down Over 100 Points; US Crude Oil Stocks Fall ↗
 
Via Benzinga
News headline image
What's Going On With UniQure Stock Wednesday? ↗
UniQure N.V. (NASDAQ:QURE) shares are trading higher Wednesday after the company announced positive topline results from Phase I/II study of AMT-130 in patients with Huntington's Disease. 
Via Benzinga
News headline image
Earnings Scheduled For July 29, 2025 ↗
 
Via Benzinga
News headline image
uniQure Earnings Preview ↗
 
Via Benzinga
News headline image
Earnings Outlook For uniQure ↗
 
Via Benzinga
Lithium Americas, Alibaba, uniQure, IREN, Cidara: Stocks Making The Biggest Moves Today ↗
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
A Cure For Huntington's Disease? UniQure Launches More Than 240%. ↗
The company's gene therapy slowed disease progression by 75% over three years. 
Via Investor's Business Daily
News headline image
uniQure Stock Doubles On Promising Data From Huntington's Disease Trial ↗
UniQure's AMT-130 gene therapy slowed Huntington's disease progression in a Phase 1/2 trial, supported by new $175 million financing for launch readiness. 
Via Benzinga
News headline image
uniQure Stock Rises Pre-Market After Investigational Huntington’s Disease Drug Slows Disease In Trial ↗
The company stated that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale. 
Via Stocktwits
News headline image
uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure's Investigational Gene Therapy Shows Promising Efficacy With Manageable Safety Risks For Fabry Disease ↗
uniQure's early AMT-191 trial data in Fabry disease showed strong enzyme activity, manageable safety, and patient independence from enzyme replacement therapy. 
Via Benzinga
News headline image
uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
From uniQure Inc.
Via GlobeNewswire
News headline image
FDA Outlines Process To Speed Up Rare Disease Therapy Approvals ↗
FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact. 
Via Benzinga
News headline image
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction ↗
Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight. 
Via Benzinga
News headline image
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? ↗
Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies. 
Via Benzinga
News headline image
uniQure Narrows Loss in Fiscal Q2 ↗
Via The Motley Fool
News headline image
uniQure NV (NASDAQ:QURE) Posts Q2 2025 Earnings: EPS Beat Offsets Revenue Miss as Regulatory Progress Boosts Shares ↗
uniQure NV reports mixed Q2 2025 results with revenue missing estimates but EPS beating forecasts. Shares rise on regulatory progress for Huntington's gene therapy AMT-130. 
Via Chartmill
News headline image
uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure to Announce Second Quarter 2025 Financial Results
uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET 
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
News headline image
uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)
From uniQure Inc.
Via GlobeNewswire
News headline image
UniQure Narrows Q1 Loss But Revenue Plummets: Retail’s In Wait-And-Watch Mode ↗
The company narrowed its first-quarter loss to $0.82 per share, down from $1.36 per share in 2024. 
Via Stocktwits
News headline image
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For May 9, 2025 ↗
 
Via Benzinga
News headline image
uniQure to Announce First Quarter 2025 Financial Results
~ uniQure to host inaugural earnings call on Friday, May 9, 2025 at 8:30 a.m. ET ~ 
From uniQure Inc.
Via GlobeNewswire
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.